Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

BACKGROUND: We evaluated Gamalate® B6 (GB6) in patients with borderline intellectual functioning (BIF) or mild intellectual development disability (IDD). PATIENTS AND METHODS: This was a prospective phase IV observational pilot study in 30 patients who underwent neuropsychological evaluation during...

Descripción completa

Detalles Bibliográficos
Autores principales: Novell, Ramón, Esteba-Castillo, Susanna, Rodriguez, Emili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048157/
https://www.ncbi.nlm.nih.gov/pubmed/32158489
http://dx.doi.org/10.7573/dic.212601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048157/
https://www.ncbi.nlm.nih.gov/pubmed/32158489
http://dx.doi.org/10.7573/dic.212601

Ejemplares similares